Consequently, SHP2 behaves as a pro-oncogenic protein in many cancer types, and PTPN11 gain-of-function mutations are relatively frequent in human tumors, such as endometrium, hematopoietic/lymphoid, melanoma, and neuroblastoma tumors. Here, PTPN11 is linked to cancer.